VALERIS
LIVE

Serial Number

99195259

Owner

Phantom Purchaser, Inc.

Attorney

Larry L. Coats

Filing Date

May 21, 2025

Add to watchlist:

No watchlists yet
View on USPTO

VALERIS Trademark

Serial Number: 99195259

VALERIS is a trademark filed by Phantom Purchaser, Inc. on May 21, 2025. The trademark is classified under Class 9 (Computers & Electronics), Class 36 (Insurance & Financial), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Phantom Purchaser, Inc. (6 trademarks)

150 Hilton Drive
Jeffersonville, IN 47130

Entity Type: 03

VALERIS, INC. (2 trademarks)

150 HILTON DRIVE
JEFFERSONVILLE, IN 47130

Entity Type: 03

Trademark Details

Filing Date

May 21, 2025

Registration Date

Not Registered

Published for Opposition

June 30, 2026

Goods & Services

Medical counseling in the field of drug therapy, side effect management, disease state management and proper administration of medication; Pharmaceutical consultation in the field of new specialty drugs; providing information to patients regarding the administration of prescription medications as a part of patient support programs offered on behalf of pharmaceutical manufacturers; Patient health care counseling and advice regarding products in the field of prescription drugs; providing online medical information regarding prescription medications as a part of patient support programs offered on behalf of pharmaceutical manufacturers; Specialty pharmacy services in the nature of pharmaceutical advice and dispensing of pharmaceuticals

Business management and administration of pharmacy reimbursement programs; Managing and administering the distribution of prescription pharmaceutical samples, namely, prescription pharmaceutical sample distribution to physicians and patients; Mail-order pharmacy services; Business management and administration of patient co-pay reimbursement programs; Business management and administration of financial assistance programs that provide patients with access to affordable medicine, namely business management and administration of enrollment and reimbursement programs for the purchase of medication and generally facilitating access to medications; Business management and administration of patient support programs; Business management and administration of patient engagement programs; Business management and administration of formulary, patient, and payer policy information; Business management and administration of educational engagements for Health Care Providers, namely, business management and administration of efforts to educate healthcare providers on medications, disease status and standard of care; Management of the distribution of clinical trial medication and supplies, namely, coordinating the delivery of such medication and supplies to clinical trial sites; Providing business marketing information regarding tracking pharmaceutical promotional programs and evaluating and determining their effectiveness; Business data management services in the field of pharmaceutical patient safety, namely, collection and compilation of information into computer database and preparation of business reports for business and regulatory compliance purposes; Outbound healthcare provider engagement services provided, namely, promoting public awareness of diseases, pharmaceutical brands, and treatment affordable options; Outbound healthcare provider engagement services, namely, marketing services in the nature of promotion of pharmaceutical manufacturers disease treatment options via social media; Providing business information in the field of tracking payer coverage policies with regards to pharmaceutical reimbursement, co-pay assistance, and patient affordability in order to enhance their market access strategies and patient support programs; Life science business strategy consulting services for assisting clients with commercial assessments, corporate and portfolio strategy, new product planning and commercialization support, and pricing and market access insights; Business assistance management and information services regarding enrolling patients of pharmaceutical manufacturers into support programs that enable patients to view, track, and manage the support program wherein the patient support program provides pharmaceutical consumer product information, payer coverage status updates, and providing business information regarding access to enrollment and reimbursement programs for the purchase of medications; Providing business information in the pharmaceutical and life science industries concerning developments in the field of co-pay assistance and patient affordability programs; the foregoing services offered to or provided on behalf of pharmaceutical and life sciences companies

Providing downloadable podcasts for educational purposes in the field of disease, pharmaceutical brands, and affordable healthcare options

Payment services, namely, reimbursement payment processing in the field of pharmaceutical financial assistance claims as a part of a program and loyalty program payment processing services provided on behalf of pharmaceutical manufacturers for the purpose of delivering benefits to patients enrolled in pharmaceutical manufacturer-sponsored financial assistance programs; Pharmacy benefit manager accumulator mitigation services, namely, pharmacy benefit management for detecting claim activity indicative of a pharmacy benefit manager attempting to abuse the use of co-pay cards by not applying amounts paid by clients towards the patient's deductible or annual out-of-pocket expense

Pharmacy benefit fraud monitoring, namely, investigation services related to pharmacy benefit insurance claims; Personal lifestyle consulting services; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication; Providing emotional counseling and emotional support services for medical patients

Outbound healthcare provider engagement services provided on behalf of pharmaceutical manufacturers, namely, providing online non-downloadable podcasts, seminars, workshops, and virtual and in-person presentations for educational purposes in the field of diseases, pharmaceutical brands, and affordable healthcare options; Educational services, namely, conducting seminars and workshops in the fields of drug therapy, side effect management, lifestyle management, disease state management and proper administration of medication; Educational services, namely, providing training programs in the field of clinical support relating to drug therapy, side effect management, disease state management and proper administration of medication

Providing quality assurance in the field of patient claims and quality control patient claim services for others for monitoring paid claims to patients from insurance or pharmaceutical entities to insure that specific business rules are being correctly applied to patient claims; Pharmacovigilance services for others, namely, scientific research and analysis in the nature of pharmaceutical product evaluation pertaining to adverse events and product quality complaints regarding pharmaceutical products, assessment of risks presented by certain pharmaceutical products or combinations thereof, and product safety testing and consultation related thereto in the field of pharmaceuticals; Pharmacovigilance services for others, namely, monitoring efficacy of pharmaceutical preparations for quality control purposes; Providing online non-downloadable software for patient support by enrolling patients of pharmaceutical manufacturers in support programs that enables the patients to view, track and manage the support program wherein the patient support program provides pharmaceutical product and medication education, medication adherence support, visibility into medication delivery and case status, injection and product educational training, access to financial assistance programs, payer coverage status updates, patient reminders and notifications; Data warehousing services; Database development services for the purpose of collecting and maintaining patient information and registry data; Database development services, for the purpose of customized data collection and maintaining related databases in the field of prescription drugs; Software as a service (SAAS) services, namely, hosting software for use by others for managing pharmaceutical drug inventory, billing and account receivables, shipping and reporting pharmaceutical drug inventory, aggregating and analyzing patient data for the purpose of connecting clinical programs with specialty drug manufacturers and call centers; Developing customized software for others for managing pharmaceutical drug inventory, billing and account receivables, shipping and reporting pharmaceutical drug inventory, aggregating and analyzing patient data for the purpose of connecting clinical programs with specialty drug manufacturers and call centers; Electronic monitoring for the pharmaceutical industry of insurance co-pay cards to detect fraud via the internet for assuring that patients who have full or partial federally funded drug coverage are excluded from utilizing co-pay cards

Filing History

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 4, 2026 GNEN
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 4, 2026 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 4, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 4, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 4, 2026 CNEA
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jun 3, 2026 AMPX
TEAS VOLUNTARY AMENDMENT RECEIVED
Jun 3, 2026 PARI
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 21, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 21, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 21, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 21, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 20, 2026 NWOS
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 17, 2025 ASGN
APPLICATION FILING RECEIPT MAILED
May 21, 2025 MAFR
NEW APPLICATION ENTERED
May 21, 2025 NWAP